KPV tripeptide retains α-MSH anti-inflammatory potency without pigmentary side effects

α-Melanocyte-stimulating hormone (α-MSH) is a potent endogenous anti-inflammatory mediator acting through MC-Rs (melanocortin receptors) expressed across the central nervous system, immune cells, and peripheral somatic tissues. It suppresses key inflammatory pathways including NF-κB activation, adhesion molecule expression, inflammatory cytokine release, chemokine receptor signaling, T-cell proliferation, and inflammatory cell migration. Despite proven efficacy in animal models of fever, contact dermatitis, cutaneous vasculitis, fibrosis, ocular inflammation, gastrointestinal inflammation, brain inflammation, allergic airway inflammation, and arthritis, the full α-MSH hormone cannot easily be translated to human therapy because its broad biological reach — most visibly its pigmentory capacity — creates unacceptable off-target effects. A fragment-based strategy targeting only the anti-inflammatory properties without receptor-mediated pigmentation represents the core therapeutic gap this work addresses.

This is a review and synthesis paper examining the published evidence on KPV (Lys-Pro-Val, C-terminal tripeptide of α-MSH) and related short peptides, including KdPT (a KPV derivative corresponding to IL-1β(193-195)), as anti-inflammatory candidates. The authors surveyed in vitro and in vivo data across multiple disease models — inflammatory skin disease, inflammatory bowel disease, allergic asthma, and arthritis — comparing the signaling profiles of KPV and KdPT against the full α-MSH hormone. No single primary experimental dataset with defined n, dose, or route is reported; the paper synthesizes existing literature to evaluate the mechanistic overlap and therapeutic potential of these receptor-independent tripeptides.

KPV lacks the entire sequence motif required for binding to any of the known MC-Rs, yet retains almost all of the anti-inflammatory capacity of the full α-MSH hormone. Crucially, KPV displays a complete absence of pigmentory action, removing the primary side-effect barrier to clinical use. Significant mechanistic similarities between anti-inflammatory signaling of α-MSH and KPV have already been experimentally demonstrated, though the precise receptor or intracellular pathway used by KPV remains unknown. KdPT, corresponding to IL-1β(193-195), is identified as a second tripeptide with potent anti-inflammatory effects, further broadening this class. Both peptides are proposed to offer a more limited — and therefore more manageable — spectrum of biological activities compared to full α-MSH.

KPV retains nearly all anti-inflammatory capacity of α-MSH despite lacking any melanocortin receptor binding motif and producing zero pigmentory activity, making it a uniquely clean anti-inflammatory candidate.

Anticipated advantageous physicochemical, pharmacokinetic, and pharmacodynamic properties, combined with expectations of low pharmaceutical production costs, reinforce the translational case for both tripeptides.